Cargando…
Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse even...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882643/ https://www.ncbi.nlm.nih.gov/pubmed/35237257 http://dx.doi.org/10.3389/fimmu.2022.766200 |
_version_ | 1784659740110880768 |
---|---|
author | Sun, Peng Wang, Yu Yang, Hang Chen, Cui Nie, Man Sun, Xiao-Qing He, Xiao-Hua Huang, Kang-Ming Huang, Jia-Jia Li, Zhi-Ming |
author_facet | Sun, Peng Wang, Yu Yang, Hang Chen, Cui Nie, Man Sun, Xiao-Qing He, Xiao-Hua Huang, Kang-Ming Huang, Jia-Jia Li, Zhi-Ming |
author_sort | Sun, Peng |
collection | PubMed |
description | Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse events (TRAEs). Herein we retrospectively evaluated the efficacy and safety of the combined regimen of anti-PD-1 antibody, anlotinib and pegaspargase “sandwich” with radiotherapy in localized NKTL. Anti-PD-1 antibody and pegaspargase at 2500 U/m(2) were administered on day 1, while anlotinib (12 mg once a day) was orally administered on days 1-14. The treatment was repeated every 3 weeks. All the eight patients included received 3 cycles of the regimen followed by radiotherapy and an additional 3 cycles. The overall response rate was 100%, and the complete response rate was 87.5%. With a median follow-up time of 35.5 months (range, 34.03-40.90 months), median PFS and OS times were not reached. The 3-year PFS and OS rates were 100% and 100%, respectively. All patients were alive at the last follow-up. No treatment-related death and no grade 4 TRAE was reported. No grade 3/4 hematological toxicity was detected, and half of the patients didn’t report any hematological toxicity. This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance. |
format | Online Article Text |
id | pubmed-8882643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88826432022-03-01 Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma Sun, Peng Wang, Yu Yang, Hang Chen, Cui Nie, Man Sun, Xiao-Qing He, Xiao-Hua Huang, Kang-Ming Huang, Jia-Jia Li, Zhi-Ming Front Immunol Immunology Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse events (TRAEs). Herein we retrospectively evaluated the efficacy and safety of the combined regimen of anti-PD-1 antibody, anlotinib and pegaspargase “sandwich” with radiotherapy in localized NKTL. Anti-PD-1 antibody and pegaspargase at 2500 U/m(2) were administered on day 1, while anlotinib (12 mg once a day) was orally administered on days 1-14. The treatment was repeated every 3 weeks. All the eight patients included received 3 cycles of the regimen followed by radiotherapy and an additional 3 cycles. The overall response rate was 100%, and the complete response rate was 87.5%. With a median follow-up time of 35.5 months (range, 34.03-40.90 months), median PFS and OS times were not reached. The 3-year PFS and OS rates were 100% and 100%, respectively. All patients were alive at the last follow-up. No treatment-related death and no grade 4 TRAE was reported. No grade 3/4 hematological toxicity was detected, and half of the patients didn’t report any hematological toxicity. This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882643/ /pubmed/35237257 http://dx.doi.org/10.3389/fimmu.2022.766200 Text en Copyright © 2022 Sun, Wang, Yang, Chen, Nie, Sun, He, Huang, Huang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sun, Peng Wang, Yu Yang, Hang Chen, Cui Nie, Man Sun, Xiao-Qing He, Xiao-Hua Huang, Kang-Ming Huang, Jia-Jia Li, Zhi-Ming Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma |
title | Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma |
title_full | Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma |
title_fullStr | Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma |
title_full_unstemmed | Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma |
title_short | Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma |
title_sort | combination of anti-pd-1 antibody, anlotinib and pegaspargase “sandwich” with radiotherapy in localized natural killer/t cell lymphoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882643/ https://www.ncbi.nlm.nih.gov/pubmed/35237257 http://dx.doi.org/10.3389/fimmu.2022.766200 |
work_keys_str_mv | AT sunpeng combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT wangyu combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT yanghang combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT chencui combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT nieman combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT sunxiaoqing combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT hexiaohua combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT huangkangming combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT huangjiajia combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma AT lizhiming combinationofantipd1antibodyanlotinibandpegaspargasesandwichwithradiotherapyinlocalizednaturalkillertcelllymphoma |